Latest News and Press Releases

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...

Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...

Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive...

- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...

Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...

SAN FRANCISCO, June 26, 2018 (GLOBE NEWSWIRE) -- In a treatment breakthrough that could lead to a large impact on the speed and cost of recovery following patient stays in intensive care units...

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....

SAN FRANCISCO, March 23, 2018 (GLOBE NEWSWIRE) -- The Alzheimer’s Foundation of America (AFA)—in collaboration with Greener Media—is hosting a workshop titled, "What Would You Do: A Sensory...

MONMOUTH JUNCTION, NJ--(Marketwired - March 20, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira...

MONMOUTH JUNCTION, NJ--(Marketwired - March 15, 2017) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...